预约演示
3 more biotechs look to cull, partner assets in hopes of forging ahead
2022-11-14
临床1期高管变更基因疗法
Prelude Therapeutics, Evaxion and Syros Pharmaceuticals are setting aside certain programs amid rocky market conditions.
Prelude Therapeutics 2Evaxion provSyros Pharmaceuticalsf biotech pipeline culls, with three more companies setting out plans this morning to shed programs in hopes that the lighter load will allow them to forge ahead in rocky market conditions.
First up was Prelude Therapeutics, an oncology biotech discontinuing development of its PRMT5 program, which encompasses two phase 1 trials assessing selective protein arginine methyltransferase 5 inhibitors called PRT543 and PRT811. The discontinuation comes as the biotech aims to channel resources to compounds that have the highest likelihood of success, according to a Nov. 14 release.
The U.S. biotPrelude Therapeuticsrograms are its CDK9 inhibitor and MCL1 Inhibitor, bothPRMT5hich are being separately studied in phase 1 trials for solid tumorprotein arginine methyltransferase 5PRT543PRT811
“With this prioritization, we believe we can geneCDK9 inhibitorCDK9 proof-of-conceMCL1linical data in the next 12 to 24 months to guide our future regulatory pathwsolid tumorsval,” said Jane Huang, M.D., Prelude’s president and chief medical officer, adding that she believes the CDK9 and MCL1 programs “offer the best chance to improve patient outcomes.”
Meanwhile, gene therapy biotech Syros Pharmaceuticals is seeking a partner for its oral CDK7 inhibitor, dubbed SY-5609. This move would “maximize the potential” of the asset, and the biotech will seek partnership opportunities while continuing dose escalation in theCDK9oing MCL1e 1 study among patients with metastatic pancreatic cancer.
The company is looking for a parSyros Pharmaceuticalsurces to push the asset forward, SyCDK7 inhibitorCDK7CEO and President NSY-5609monian, M.D., said on a Nov. 14 earnings call. Development will continue for SY-5609 among patients who have colorectal cancer in a Roche-partnered phase 1/1b trial.metastatic pancreatic cancer
Syros will instead channel its internal resources toward its late-stage hematology porSyroso, which includes programs in higher-risk myelodysplastic syndrome, acute myelodysplastic syndrome and aSY-5609omyelocytic leukemia.colorectal cancerRoche
Syroson is another company that is not quite ready to say goodbye to any programs. Instead, its strategic focus on its “clinical leadmyelodysplastic syndrometnacute myelodysplastic syndromeut-liacute promyelocytic leukemiaEVX-01 and EVX-02/03 once it's provided clinical proof of concept data. The Danish biotech also intends to hand off some early-stage infectious disease programs, such as its Staphylococcus aureus vaccine, to others.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。